Drug eluting grafts for hemodialysis access

Area of Science:

• Biomaterials Science
• Vascular Surgery
• Drug Delivery Systems

Background:

• Arteriovenous (AV) access grafts are crucial for hemodialysis but prone to complications like neointimal hyperplasia, infection, and thrombosis.
• Current prosthetic grafts, such as heparin-coated expanded polytetrafluoroethylene (ePTFE), offer some protection against early thrombosis.
• Significant unmet needs exist for improved graft materials that address multiple failure modes.

Purpose of the Study:

• To review advancements in drug-eluting graft technology for enhanced AV access.
• To highlight novel approaches targeting key complications in prosthetic grafts.
• To explore the potential of next-generation therapies, including gene therapy, for vascular access.

Main Methods:

• Review of current literature on drug-eluting grafts for AV access.
• Analysis of research into materials and coatings designed to reduce neointimal hyperplasia, infection, and thrombogenicity.
• Examination of emerging technologies such as paclitaxel-eluting, antibiotic-eluting, and gene therapy-eluting grafts.

Main Results:

• Heparin-coated ePTFE grafts are currently the only approved drug-eluting option, demonstrating efficacy in reducing early thrombosis.
• Emerging drug-eluting grafts incorporating paclitaxel and antibiotics show promise in preclinical and early clinical studies.
• Hybrid coated grafts capable of delivering targeted gene therapies represent a promising future direction.

Conclusions:

• New drug-eluting graft technologies offer significant potential to improve AV access graft survival and function.
• Addressing neointimal hyperplasia, infection, and thrombogenicity simultaneously is key to advancing graft performance.
• Future research into advanced drug and gene delivery systems will likely revolutionize vascular access management.